{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:43:47Z","timestamp":1785797027972,"version":"3.56.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002738","name":"APHP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.rpth.2025.102685","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T18:29:28Z","timestamp":1737224968000},"page":"102685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Thromboprophylaxis in multiple myeloma"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2163","authenticated-orcid":false,"given":"Laurent","family":"Frenzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.102685_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102571","article-title":"Multiple myeloma: retrospective assessment of routine thromboprophylaxis and utility of thrombotic risk scores","volume":"8","author":"Fernandez-Vargas","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102685_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.thromres.2023.11.021","article-title":"Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: results of a large survey and clinical guidance recommendations from the IFM group","volume":"233","author":"Frenzel","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.102685_bib2","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102685_bib3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjh.18452","article-title":"Vascular thrombotic events in the era of modern myeloma therapy","volume":"199","author":"Mai","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102685_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rpth.2025.102685_bib5","first-page":"2720","article-title":"Incidence of venous thromboembolism in multiple myeloma patients across different regimens: role of procoagulant microparticles and cytokine release","volume":"11","author":"Gidaro","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.rpth.2025.102685_bib6","article-title":"Supportive care in multiple myeloma: current practices and advances","volume":"29","author":"Miceli","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.rpth.2025.102685_bib8","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2025.102685_bib9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bjh.18630","article-title":"External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs","volume":"201","author":"Dima","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102685_bib10","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood.2022015727","article-title":"Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score","volume":"140","author":"Chakraborty","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102685_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MCP.0b013e3281eb8ef0","article-title":"The effects of race\/ethnicity and sex on the risk of venous thromboembolism","volume":"13","author":"Keenan","year":"2007","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.rpth.2025.102685_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/cancers12010191","article-title":"Multiple myeloma and thrombosis: prophylaxis and risk prediction tools","volume":"12","author":"Fotiou","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rpth.2025.102685_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clml.2020.11.015","article-title":"Thromboembolism incidence and risk factors in multiple myeloma after first exposure to immunomodulatory drug-based regimens","volume":"21","author":"Patel","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.rpth.2025.102685_bib14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.rpth.2025.102685_bib15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.19017","article-title":"Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: a systematic review and updated meta-analysis","volume":"203","author":"Costa","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102685_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2022.03.001","article-title":"Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: a prospective cohort study","volume":"213","author":"Sayar","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.102685_bib17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ajh.25459","article-title":"Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study","volume":"94","author":"Pegourie","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2025.102685_bib18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjh.16653","article-title":"Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents","volume":"190","author":"Cornell","year":"2020","journal-title":"Br J Haematol"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925000093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925000093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T23:52:52Z","timestamp":1751932372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2475037925000093"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102685","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thromboprophylaxis in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102685","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102685"}}